Search clinical trials for: SM-13496 (lurasidone HCl)

Total 29 results

Sumitomo Pharma Co., Ltd.

Completed

A Phase III Study of SM-13496 in Patients With Bipolar I Depression.

Bipolar Depression

Lithuania, Malaysia, Russian Federation, Slovakia, Ukraine, Japan, Philippines, Taiwan
Sumitomo Pharma Co., Ltd.

Completed

Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

Schizophrenia

Japan, Korea, Republic of, Taiwan
Sumitomo Pharma Co., Ltd.

Completed

A Phase III Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

Schizophrenia

Japan, Korea, Republic of, Malaysia, Taiwan
Sumitomo Pharma Co., Ltd.

Completed

A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder.

Bipolar I Disorder

Japan, Lithuania, Malaysia, Philippines, Russian Federation, Slovakia, Taiwan, Ukraine
Sumitomo Pharma Co., Ltd.

Completed

Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

Schizophrenia

Japan, Korea, Republic of, Malaysia, Taiwan
Sunovion

Completed

A Study to Determine the Maximum Tolerated Dose of an Investigational Drug in Subjects With Schizophrenia

Schizophrenia

United States
Sunovion

Completed

Lithium Drug-Drug Interaction Study With Lurasidone HCl

Schizophrenia

United States
Sunovion

Completed

Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl

Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder

United States
Sumitomo Pharma (Suzhou) Co., Ltd.
Sunovion

Terminated

A Study of Lurasidone Compared With Placebo for the Treatment of Bipolar I Depression

Bipolar I Depression

China
Sunovion

Completed

A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder (Switch Ext)

Schizophrenia | Schizoaffective Disorder

United States
Sunovion

Completed

Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia

Schizophrenia

United States, Malaysia, Ukraine, India, Romania, Russian Federation, France
Sumitomo Pharma (Suzhou) Co., Ltd.

Completed

The Safety and Effectiveness of Latuda® Post-marketing Surveillance in the Treatment of Chinese Schizophrenia Patients

Schizophrenia

China
Sunovion

Completed

Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia

Schizophrenia | Schizoaffective Disorder

United States, Israel, Chile, South Africa, Argentina, Brazil, Croatia, Thailand
Sunovion

Completed

The Bioequivalence Of Two Different Lurasidone Formulations In Patients

Schizophrenia

United States
Sunovion

Completed

Midazolam Drug-Drug Interaction Study With Lurasidone HCl

Schizophrenia Patients

United States
NeuroRx, Inc.
Target Health Inc.

Active, not recruiting

NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation (SBD-ASIB)

Suicidal Ideation | Bipolar Depression

United States
Sunovion

Completed

A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents (SWITCHCore)

Schizophrenia | Schizoaffective Disorder

United States
Sunovion

Completed

Rifampin Drug-Drug Interaction Study With Lurasidone HCl

Male, Healthy Normal Subjects

United States
NeuroRx, Inc.

Not yet recruiting

NRX-101 for Complicated Urinary Tract Infection (UTI) Including Pyelonephritis

Urinary Tract Infections | Pyelonephritis
NeuroRx, Inc.
Prevail Infoworks, Inc

Completed

NRX-101 for Bipolar Depression With Subacute Suicidal Ideation

Bipolar Depression | Suicidal Ideation and Behavior

United States
NeuroRx, Inc.
Target Health Inc.

Completed

NRX101 Glx Biomarker Validation Study (NRX-GLX)

Suicidal Ideation | Bipolar Depression

United States
Bukwang Pharmaceutical

Completed

A 6-week Study to Evaluate the Efficacy and Safety of Lurasidone HCL in Acutely Psychotic Patients With Schizophrenia

Schizophrenia

Korea, Republic of
Sunovion

Completed

Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia (PEARL 3 Ext)

Chronic Schizophrenia

United States, Colombia, India, Ukraine, Russian Federation, Romania
National Cancer Institute (NCI)

Terminated

Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia in Remission | Adult Acute Monoblastic Leukemia | Adult Acute Monocytic Leukemia and other conditions

Canada
National Cancer Institute (NCI)
Children's Oncology Group

Completed

Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome

United States
National Cancer Institute (NCI)

Completed

Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome | Myelodysplastic Syndrome With Excess Blasts | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome | Adult Acute Monoblastic Leukemia | Adult Acute Monocytic Leukemia | Adult Acute Myeloid Leukemia... and other conditions

United States
National Cancer Institute (NCI)

Completed

Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center

Completed

DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Hematopoietic and Lymphoid Cell Neoplasm | Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic Syndrome | Recurrent Acute Lymphoblastic... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement

B Acute Lymphoblastic Leukemia | Acute Leukemia of Ambiguous Lineage | Mixed Phenotype Acute Leukemia

United States, Canada, Puerto Rico, Australia

Search clinical trials for: SM-13496 (lurasidone HCl)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations